Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease

Journal of Nephrology

Volumn 22, Issue 6, 2009, Pages 774-782

  Matsubara, Keisuke ^a   Stenvinkel, Peter ^a   Qureshi, Abdul Rashid ^a   Carrero, Juan Jesús ^a   Axelsson, Jonas ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Alvestrand, Anders ^a   Lindholm, Bengt ^a   Suliman, Mohamed E ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Cardiovascular disease; Carotid plaques; Chronic kidney disease; Endothelial dysfunction; Inflammation; Mortality; Osteoprotegerin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRON; OSTEOPROTEGERIN; PENTOSIDINE; PENTRAXIN 3; PHOSPHATE; POTASSIUM; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN B GROUP; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN ENERGY WASTING; SURVIVAL RATE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPROTEGERIN; OXIDATIVE STRESS; PROPORTIONAL HAZARDS MODELS; PROTEIN-ENERGY MALNUTRITION; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 72149103269     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
3. Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial. 2007;20:139-143.
4. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456-469.
5. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67:2295-2304.
6. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560-567.
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
8. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
9. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463-474.
10. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616.
11. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641.
12. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
13. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002;521:180-184.
14. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin: clinical relevance and potential applications. Eur J Endocrinol. 2001;145:681-683.
15. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-2180.
16. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518.
17. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-1028.
18. Erdogan B, Aslan E, Bagis T, et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. Neurol Res. 2004;26:658-661.
19. Kazama JJ. Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens. 2004;13:411-415.
20. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;42:303-309.
21. Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1886-1889.
22. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006;17:262-270.
23. Hjelmesaeth J, Ueland T, Flyvbjerg A, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol. 2006;17:1746-1754.
24. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int. 2001;59:407-414.
25. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168-175.
26. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006;55:2126-2131.
27. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911.
28. Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in endstage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614-1622.
29. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr. 1987;11:8-13.
30. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin 6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002;39:274-282.
31. Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005;67:1576-1582.
32. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549-553.
33. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57-66.
34. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;76:199-206.
35. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8:504-512.
36. Mangan SH, Campenhout AV, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res. 2007.
37. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326-330.
38. Zickler D, Boenisch O, Otto N, Schindler R. The pentraxins C-reactive protein and pentraxin3 augment calcification of human vascular smooth muscle cells in vitro. Blood Purif. 2007;25:340.
39. Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:976-985.